Global Primary Hyperoxaluria Drug Market Size By Type (ALLN-230, DCR-PHXC), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Primary Hyperoxaluria Drug Market was valued at USD 220 million in 2023 and is projected to surpass USD 695 million by 2031, expanding at a CAGR of 15.4% from 2023 to 2031. The market growth is fueled by the increasing prevalence of rare genetic disorders, rising awareness and diagnosis of primary hyperoxaluria (PH), and the growing adoption of RNA interference (RNAi) therapies. The launch of novel therapies targeting the oxalate production pathway and a robust pipeline of drug candidates are further propelling market expansion. In addition, regulatory incentives for orphan drug development are enhancing pharmaceutical interest in this niche segment.

Drivers:

1. Increasing Diagnosis and Awareness of Rare Diseases:

Enhanced genetic screening, rising awareness campaigns, and improved healthcare infrastructure are driving early diagnosis of primary hyperoxaluria, leading to increased treatment rates and demand for targeted therapies.

2. Breakthroughs in RNAi Therapeutics:

RNA interference-based drugs, like lumasiran, have shown remarkable efficacy in reducing urinary oxalate levels. The expanding acceptance of RNAi platforms is fueling drug development and commercial success.

3. Orphan Drug Designation and Regulatory Support:

Favorable policies such as priority reviews, market exclusivity, and tax incentives under orphan drug designations are attracting major pharmaceutical players to invest in this rare disease market.

Restraints:

1. High Cost of Therapy:

RNAi therapies and other biologics come with high development and treatment costs, limiting accessibility, especially in developing economies. Reimbursement issues further constrain market penetration.

2. Limited Patient Pool:

As a rare autosomal recessive disorder, primary hyperoxaluria has a relatively small patient base, posing challenges for commercial scalability and ROI for drug developers.

Opportunity:

1. Expansion into Emerging Markets:

With increasing healthcare investment and diagnostic capabilities, emerging regions like Asia-Pacific and Latin America offer untapped potential for market growth.

2. Advancements in Gene Therapy:

Ongoing research in gene-editing technologies such as CRISPR/Cas9 provides future potential for curative treatment, presenting transformative opportunities for market players.

3. Strategic Collaborations:

Partnerships between biotech firms and large pharmaceutical companies are accelerating innovation and global reach, particularly in developing novel delivery mechanisms for RNAi therapies.

Market by System Type Insights:

Based on drug type, the RNAi Therapeutics segment dominated the market in 2023, led by the commercial success of FDA-approved drugs such as lumasiran. These drugs act by silencing genes responsible for excessive oxalate production, thus addressing the root cause of the disease. The Gene Therapy segment is anticipated to witness the highest growth, supported by ongoing clinical trials and increasing investment in curative solutions.

Market by End-Use Insights:

By end-use, Hospitals and Specialty Clinics emerged as the primary distribution channel in 2023, accounting for over 60% of the market share. These centers are crucial for diagnosis, treatment, and long-term management of primary hyperoxaluria. The Homecare Settings segment is expected to grow rapidly due to patient preference for subcutaneous administration and the convenience of self-injection therapies like lumasiran.

Market by Regional Insights:

North America led the market in 2023, supported by robust research infrastructure, favorable reimbursement policies, and early adoption of novel therapeutics. However, Europe is also gaining momentum with the increasing approval of orphan drugs and presence of supportive regulatory frameworks. Asia-Pacific is projected to be the fastest-growing region due to growing awareness, improving healthcare infrastructure, and expansion of key players into developing countries.

Competitive Scenario:

Prominent players in the Global Primary Hyperoxaluria Drug Market include:

Alnylam Pharmaceuticals, Inc.

Dicerna Pharmaceuticals (acquired by Novo Nordisk)

OxThera AB

Allena Pharmaceuticals

Chinook Therapeutics

These companies are focusing on RNAi-based product development, strategic licensing agreements, and expanding their geographic reach. Noteworthy developments include:

2023: Alnylam received expanded FDA approval for lumasiran in treating pediatric patients with PH1.

2024: Novo Nordisk initiated a Phase III trial for nedosiran, targeting broader patient populations.

2025: OxThera's Oxabact entered late-stage clinical trials targeting PH type 2 and 3.

Scope of Work – Global Primary Hyperoxaluria Drug Market

Report Metric Details

Market Size (2023) USD 220 million

Projected Market Size (2031) USD 695 million

CAGR (2023–2031) 15.4%

Market Segments Drug Type (RNAi Therapeutics, Gene Therapy), End-Use (Hospitals, Homecare)

Growth Drivers RNAi breakthroughs, rising PH diagnosis, orphan drug incentives

Opportunities Emerging markets, gene therapy innovation, strategic collaborations

Key Market Developments:

Nov 2023: Alnylam received EMA approval to extend the indication of lumasiran to adolescent patients.

Aug 2024: Novo Nordisk initiated global distribution partnerships for nedosiran across Latin America.

Jan 2025: OxThera began collaboration with a European university hospital network to accelerate late-stage trials.

FAQs:

1) What is the current market size of the Global Primary Hyperoxaluria Drug Market?

The market size was valued at USD 220 million in 2023.

2) What is the major growth driver of the Global Primary Hyperoxaluria Drug Market?

The market is primarily driven by RNAi therapy advancements and increased diagnosis of PH.

3) Which is the largest region during the forecast period in the Global Primary Hyperoxaluria Drug Market?

North America is expected to maintain dominance due to strong research and healthcare ecosystems.

4) Which segment accounted for the largest market share in the Global Primary Hyperoxaluria Drug Market?

The RNAi Therapeutics segment held the largest share in 2023.

5) Who are the key market players in the Global Primary Hyperoxaluria Drug Market?

Leading companies include Alnylam Pharmaceuticals, Novo Nordisk, OxThera AB, and Allena Pharmaceuticals.